Form 4 for CVRX CVRx, Inc.
Accepted 2023-10-18 00:00:00 ET · period of report 2023-10-16 · accession 0001415889-23-014406 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-10-18 | 2023-10-16 | CVRX | Galle Liz | VP OF Gbl CLINICAL RESEARCH | M - OptEx | $0.24 | +778 | 778 | New | +$186.72 |
| D | 2023-10-18 | 2023-10-16 | CVRX | Galle Liz | VP OF Gbl CLINICAL RESEARCH | M - OptEx | $0.00 | -778 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-10-16 | M | A | 778 | $0.24 | 778 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2023-10-16 | M | D | 778 | $0.00 | 0 | D | $0.24 · — to 2023-11-11 | 778 Common Stock | (F1) Fully vested. |